Evaluation of the Effect of LY3871801 on the Pharmacokinetics of CYP450 Substrates and an OAT1/3 Substrate in Healthy Participants
Latest Information Update: 20 Apr 2023
At a glance
- Drugs Ocadusertib (Primary) ; Dextromethorphan; Methotrexate; Midazolam; Repaglinide; Warfarin
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 14 Apr 2023 Status changed from recruiting to completed.
- 26 Dec 2022 Planned End Date changed from 17 Mar 2023 to 19 Mar 2023.
- 26 Dec 2022 Planned primary completion date changed from 17 Mar 2023 to 19 Mar 2023.